Lombard puts funds into US Aorfix bid
This article was originally published in Clinica
UK cardiovascular device make Lombard Medical Technologies last week announced completion of a £7.4.m ($14m) gross (£6.6m net) ordinary share placing and said the new funds would help it get closer to a US approval of its AAA stent graft, Aorfix. "The aim is to have completed patient enrolment by this time next year and to have filed a PMA after one-year patient follow-up by mid-2009," Lombard CEO Brian Howlett told Clinica. This schedule could theoretically allow for a PMA approval before the end of 2009.